Compare RYZ & NBTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RYZ | NBTX |
|---|---|---|
| Founded | 1842 | 2003 |
| Country | United States | France |
| Employees | 4300 | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.0B |
| IPO Year | 2014 | 2018 |
| Metric | RYZ | NBTX |
|---|---|---|
| Price | $28.29 | $39.72 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | N/A | ★ $36.00 |
| AVG Volume (30 Days) | ★ 349.5K | 75.3K |
| Earning Date | 05-06-2026 | 03-31-2026 |
| Dividend Yield | ★ 2.82% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $75.79 | $58.17 |
| Revenue Next Year | $2.17 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $19.34 | $4.10 |
| 52 Week High | $29.03 | $57.14 |
| Indicator | RYZ | NBTX |
|---|---|---|
| Relative Strength Index (RSI) | 60.96 | 48.15 |
| Support Level | $23.47 | $38.89 |
| Resistance Level | $29.03 | $41.89 |
| Average True Range (ATR) | 1.15 | 3.32 |
| MACD | 0.23 | -1.31 |
| Stochastic Oscillator | 88.90 | 6.08 |
Ryerson Holding Corp provides a metals service center, and value-added processor and is a distributor of industrial metals with operations in the United States, Canada, and Mexico. In addition to its North American operations, it conducts processing and distribution operations in China. It carries a full line of products in stainless steel, aluminum, carbon steel, and alloy steels and a limited line of nickel and red metals in various shapes and forms. The company has one operating and reportable segment, metals service centers. It derives substantially all of its sales from the processing and distribution of met. Geographically, the majority revenue is generated from the United States.
Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.